Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation.
In this study an attempt was made to prepare mucoadhesive microcapsules of gliclazide using various mucoadhesive polymers designed for oral controlled release. Gliclazide microcapsules were prepared using sodium alginate and mucoadhesive polymer such as sodium carboxymethyl cellulose (sodium CMC), carbopol 934P or hydroxy propylmethyl cellulose (HPMC) by orifice-ionic gelation method. The microcapsules were evaluated for surface morphology and particle shape by scanning electron microscope. Microcapsules were also evaluated for their microencapsulation efficiency, in vitro wash-off mucoadhesion test, in vitro drug release and in vivo study. The microcapsules were discrete, spherical and free flowing. The microencapsulation efficiency was in the range of 65-80% and microcapsules exhibited good mucoadhesive property in the in vitro wash off test. The percentage of microcapsules adhering to tissue at pH 7.4 after 6 h varied from 12-32%, whereas the percentage of microcapsules adhering to tissue at pH 1.2 after 6 h varied from 35-68%. The drug release was also found to be slow and extended for more than 16 h. In vivo testing of the mucoadhesive microcapsules in diabetic albino rats demonstrated significant antidiabetic effect of gliclazide. The hypoglycemic effect obtained by mucoadhesive microcapsules was for more than 16 h whereas gliclazide produced an antidiabetic effect for only 10 h suggesting that mucoadhesive microcapsules are a valuable system for the long term delivery of gliclazide.
Prajapati
S K
SK
Department of Pharmaceutics, Institute of Pharmacy, Bundelkhand University, Jhansi, Uttar Pradesh, India.
Tripathi
Purnima
P
Ubaidulla
Udhumansha
U
Anand
Vikas
V
D000278:Administration, Buccal; D000818:Animals; D002214:Capsules; D002610:Cheek; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry*; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy*; D004058:Diffusion; D004339:Drug Compounding / Q000379:methods; D004353:Drug Evaluation, Preclinical; D005260:Female; D005907:Gliclazide / Q000008:administration & dosage / Q000737:chemistry*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry; D008297:Male; D008422:Materials Testing; D009061:Mouth Mucosa; D051381:Rats; D013812:Therapeutics; D014014:Tissue Adhesives / Q000737:chemistry*
D002214:Capsules; D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D014014:Tissue Adhesives; D005907:Gliclazide